Autoimmune Diseases  >>  methylprednisolone sodium succinate  >>  Phase 2
Welcome,         Profile    Billing    Logout  

7 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
methylprednisolone sodium succinate / Generic mfg.
SIERRA, NCT00282308: A Study to Evaluate the Effects of Rituximab on Immune Responses in Subjects With Active Rheumatoid Arthritis Receiving Background Methotrexate

Completed
2
103
US
Rituximab, Rituxan, MabThera, Methotrexate, Methylprednisone, C. albicans, Tetanus toxoid adsorbed booster vaccine, 23-valent pneumococcal polysaccharide vaccine, Keyhole limpet hemocyanin
Genentech, Inc.
Rheumatoid Arthritis
01/08
05/12
RUMBA, NCT00243412: A Study of the Safety and Efficacy of Rituximab in Patients With Moderate to Severe Rheumatoid Arthritis Receiving Methotrexate

Completed
2
42
US
folate, methotrexate, methylprednisolone, Placebo, Rituximab
Genentech, Inc.
Rheumatoid Arthritis
02/09
02/09
NCT00298272: Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis

Terminated
2
54
US
IDEC-C2B8 (rituximab), Rituxan, Placebo, Methotrexate, Etanercept, Enbrel, Adalimumab, Humira, Methylprednisolone, Folate
Biogen, Hoffmann-La Roche, Genentech, Inc.
Rheumatoid Arthritis
04/09
07/11
NCT00423098 / 2006-002107-13: Efficacy and Safety of Enteric-coated Mycophenolate Sodium in Combination With Two Corticosteroid Regimens for the Treatment of Lupus Nephritis Flare

Completed
2
81
Europe, RoW
Mycophenolate sodium, Myfortic, Prednisone, Methylprednisolone
Novartis Pharmaceuticals
Lupus Nephritis
11/09
11/09
NCT00556192: Can Targeted Elimination of B-cell Depletion Therapy and/or Combination Therapy on Systemic Lupus Erythematosus

Completed
2
20
RoW
rituximab, Mabthera
Chinese University of Hong Kong
Systemic Lupus Erythematosus
12/09
12/09
NCT01039103 / 2009-013884-21: Nanocort in Acute Exacerbation of Relapsing-Remitting Multiple Sclerosis (MS)

Terminated
2
15
Europe
PEG-liposomal prednisolone sodium phosphate, Nanocort, Methylprednisolone, Solu-Medrol
Galapagos NV
Acute Exacerbation of Remitting Relapsing Multiple Sclerosis, Clinically Isolated Syndrome
11/11
11/11
RESTORE, NCT01071083 / 2009-017490-38: Treatment Interruption of Natalizumab

Checkmark Interim Data AAN (MS)
Mar 2012 - Mar 2012: Interim Data AAN (MS)
Completed
2
175
US, Europe
natalizumab, interferon beta 1-a, methylprednisolone, IV placebo, glatiramer acetate
Biogen, Elan Pharmaceuticals
Relapsing Remitting Multiple Sclerosis
11/11
11/11

Download Options